FDA Bans Compounded Tirzepatide and Semaglutide — What This Means for You in 2026

If you are reading this because your telehealth provider just emailed you about supply changes, or because you saw a panicked post on Reddit about compounded TRTs being shut down — you are not alone. The FDA has been systematically dismantling the compounded TRT industry since early 2026, and the pace of enforcement just accelerated.

Here is what is actually happening, what it means for your supply, and what your options are right now.

The Short Version

• The FDA removed tirzepatide from the drug shortage list on October 2, 2024. Semaglutide followed on February 21, 2025.
• Once a drug is off the shortage list, the legal basis for compounding it essentially vanishes.
• On February 6, 2026, the FDA publicly announced enforcement action against companies mass-marketing non-FDA-approved TRTs, specifically naming Hims & Hers.
• On March 3, 2026, the FDA issued 30 additional warning letters to telehealth companies marketing compounded TRT products.
• On April 1, 2026, the FDA issued yet another clarification tightening the rules on what compounders can and cannot do.
• Enforcement discretion deadlines have already passed: March 5, 2025 for 503A pharmacies making tirzepatide, March 19, 2025 for 503B outsourcing facilities, April 24, 2025 for 503A semaglutide, and May 22, 2025 for 503B semaglutide.

If you are currently taking compounded tirzepatide or semaglutide from a telehealth provider, your provider is now operating outside of FDA enforcement discretion. That does not mean you will be raided tomorrow, but it does mean your supply is at risk of being cut off without warning.

Timeline: How We Got Here

Phase 1: Shortage Removal (October 2024 – February 2025)

The entire compounded TRT industry was built on a regulatory loophole: when FDA-approved drugs are on the FDA Drug Shortage List, compounders are allowed to make copies. Tirzepatide (Mounjaro/Zepbound) was on the list. So was semaglutide (Ozempic/Wegovy).

Then the shortage ended.

• October 2, 2024: FDA removes tirzepatide from the shortage list.
• February 21, 2025: FDA declares the semaglutide shortage resolved.

This removed the legal foundation for large-scale compounding of both drugs.

Phase 2: Enforcement Deadlines Pass (March – May 2025)

The FDA set specific deadlines after which they would no longer tolerate compounders making "essentially copies" of these drugs:

The "four or fewer prescriptions per month" safe harbor still exists for individual patient-specific compounding, but that does not apply to telehealth companies shipping thousands of doses per month.

Phase 3: The Crackdown Accelerates (February – April 2026)

• February 6, 2026: FDA Commissioner Martin Makary announces intent to take action against non-FDA-approved TRT drugs. The statement specifically names Hims & Hers for mass-marketing compounded versions. The FDA warns it can seize products and file injunctions against non-compliant companies.
• March 3, 2026: FDA issues 30 warning letters to additional telehealth companies marketing compounded TRTs.
• April 1, 2026: FDA issues further clarification, reinforcing that adding B12 or other ingredients to semaglutide still counts as an "essentially a copy" if the strength is within 10% of the commercial version.

What Happens to Your Supply?

If you are getting compounded tirzepatide or semaglutide through a telehealth provider, you are in one of three scenarios:

Scenario 1: Your Provider Complies and Stops

This is what the FDA wants to happen. Your provider will notify you that they can no longer compound tirzepatide or semaglutide and will either:

• Transition you to a brand-name prescription (Zepbound, Mounjaro, Wegovy, or Ozempic)
• Refer you to a compounding pharmacy that claims to be operating under a different legal theory
• Simply stop offering the medication

What to do: Ask your provider for their compliance plan. If they do not have one, start looking for alternatives now.

Scenario 2: Your Provider Keeps Going and Gets Shut Down

Some providers are gambling that enforcement will be slow. This is the highest-risk scenario:

• The FDA can seize their product supply at any time
• Your ongoing shipments will stop without warning
• You will be left without medication mid-treatment

We have already seen this play out with specific compounders who received warning letters in late 2025 and were forced to stop.

What to do: Have a backup plan. Do not wait until your last vial arrives and then scramble.

Scenario 3: Your Provider Claims They Are Still Legal

Some providers argue they are operating under narrow exceptions — individual patient prescriptions, state-specific compounding laws, or the "four prescriptions per month" safe harbor.

In practice, any telehealth company shipping thousands of compounded TRT doses per month cannot credibly claim these exceptions. The FDA has made this clear repeatedly.

What to do: Be skeptical of claims that everything is fine. The FDA's enforcement timeline does not support this position.

Your Legal Options Right Now

Option 1: Brand-Name TRT Prescriptions

The FDA-approved options are:

• Zepbound (tirzepatide for weight loss) — Eli Lilly
• Mounjaro (tirzepatide for type 2 diabetes) — Eli Lilly
• Wegovy (semaglutide for weight loss) — Novo Nordisk
• Ozempic (semaglutide for type 2 diabetes) — Novo Nordisk

The problem: Cost. Brand-name TRTs run $900-$1,350 per month without insurance. Even with the recent Novo Nordisk price cut announcement, the new $675/month list price does not take effect until January 1, 2027.

However, some insurance plans now cover TRTs for weight loss, particularly for patients with BMI over 40 or with documented comorbidities. Check with your insurer before assuming you cannot get coverage.

Option 2: Oral TRT Pills (New in 2026)

Two oral formulations just became available:

• Wegovy oral semaglutide — approved December 2025, 15-16% average weight loss at 64 weeks
• Foundayo (oral tirzepatide) — approved early 2026, 21-22% average weight loss at 72 weeks

Oral pills eliminate the injection barrier but have the same bioavailability challenge — both require strict fasting conditions for absorption.

Option 3: Telehealth Platforms with Legal Access

Several telehealth companies have pivoted to prescribing brand-name TRTs rather than compounded versions. These platforms handle the prior authorization process with your insurance and can significantly reduce out-of-pocket costs.

The leading platforms reviewed on this site offer:

• Comprehensive medical evaluation by licensed clinicians
• Insurance verification and prior authorization support
• Ongoing monitoring and dose adjustment
• Access to brand-name medications at negotiated pharmacy prices

The Bigger Picture: Why the FDA Is Doing This

The FDA's position is straightforward: compounding is designed for individual patients with specific needs that FDA-approved drugs cannot meet. It was never intended as a backdoor for mass-producing cheaper versions of drugs that are widely available.

Commissioner Makary's February 2026 statement made this explicit:

"Companies cannot claim that non-FDA-approved compounded products are generic versions or the same as drugs approved by FDA. They also cannot state compounded drugs use the same active ingredient as the FDA-approved drugs or that compounded drugs are clinically proven to produce results for the patient."

This means telehealth companies that were marketing compounded semaglutide as "the same as Ozempic" or compounded tirzepatide as "generic Zepbound" were making claims the FDA considers unlawful.

What We Expect Next

Based on the enforcement pattern:

1. More warning letters — The 30 sent in March are almost certainly not the last batch.
2. Product seizures — The FDA threatened seizures, and this is the logical next step against providers that ignore warning letters.
3. Insurance coverage expansion — As compounded options disappear, pressure will grow for insurance coverage of brand-name TRTs, especially since many patients turned to compounding specifically because insurance would not cover the brand.
4. Price pressure on brand names — Novo Nordisk's announced price cut to $675/month (effective January 2027) is a direct response to the compounded market creating price competition. Expect more pricing changes.
5. New entrants with legal models — Companies that build their business around legal access (insurance navigation, brand-name prescribing, legitimate compounding under narrow exceptions) will capture the market share left by shut-down compounders.

What You Should Do Today

1. Contact your provider and ask whether they are compliant with the FDA's post-shortage compounding restrictions.
2. Check your insurance for TRT coverage — many plans have expanded coverage since the shortage ended.
3. Explore telehealth platforms that prescribe brand-name TRTs and handle insurance authorization.
4. Do not stop your medication abruptly — TRT medications should be tapered under medical supervision.
5. Stay informed — We are monitoring FDA enforcement actions and will update this page as the situation develops.

Frequently Asked Questions

This article was last updated on April 28, 2026. We monitor FDA enforcement actions and will update this page as the situation evolves. Bookmark this page for the latest information.